Swissmedic news highlights February 2026

5 March 2026

From the Swissmedic newsfeed, Arex Advisor has rounded up a selection of regulatory highlights from the past month. 

Swissmedic reports rise in illegal medicine imports in 2025

16 February 2026
Swissmedic recorded a 17% increase in illegal medicinal product imports in 2025 compared with 2024, handling 6,647 consignments in collaboration with the Federal Office for Customs and Border Security and other authorities. While overall volumes have remained relatively stable in recent years, shifts in product types and countries of origin highlight evolving risks and the ongoing public health concerns linked to illegal imports. Read more

40 new active substances authorised in 2025

17 February 2026
Swissmedic authorised 40 human medicinal products containing new active substances for the Swiss market in 2025. The median turnaround time fell to 392 calendar days, 12% faster than in 2024, with a quarter of approvals processed through international procedures, highlighting continued efficiency gains and global collaboration in assessments. Read more

How do these changes affect you?

Our experienced specialists are ready to help you navigate the regulatory landscape!

Staffan Thunell

Founding partner

BSc Economics and BA

Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from posit­ions as Founder, Chair­man, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.